Second, the sample size was relatively small; however, this would be an inherent limitation at most centers that generally do not have many patients with high PD‐L1 expression who are undergoing first‐line pembrolizumab monotherapy for NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.